Scholarlink

<p>Ultra long-acting beta-agonists (ULABAs) have emerged as key therapeutic agents in the management of chronic obstructive pulmonary disease (COPD) and asthma, offering prolonged bronchodilation and symptom control in adults. Their extended duration of action, often exceeding 24&#xa0;h, reduces the need for frequent dosing, enhancing adherence and simplifying treatment regimens. However, the use of ULABAs in children presents unique challenges, including age-specific pharmacodynamics, safety concerns, and the need for appropriate combination therapies with inhaled corticosteroids. Current research suggests potential benefits in improving lung function and the quality of life, yet robust evidence remains limited. Regulatory guidelines vary, emphasizing the cautious application of ULABAs in children, particularly under 12&#xa0;years, due to concerns about adverse effects and optimal dosing. Future research should address these gaps, focusing on long-term safety, efficacy, and the role of personalized approaches to optimize asthma outcomes in this vulnerable population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current Status of Ultra Long-Acting Beta Agonists in Children

  • 期刊论文

  • 发表日期：

    2025年7月23日

查看全文
  • Ramakrishna Golla,
  • Ketan Kumar

摘要

Ultra long-acting beta-agonists (ULABAs) have emerged as key therapeutic agents in the management of chronic obstructive pulmonary disease (COPD) and asthma, offering prolonged bronchodilation and symptom control in adults. Their extended duration of action, often exceeding 24 h, reduces the need for frequent dosing, enhancing adherence and simplifying treatment regimens. However, the use of ULABAs in children presents unique challenges, including age-specific pharmacodynamics, safety concerns, and the need for appropriate combination therapies with inhaled corticosteroids. Current research suggests potential benefits in improving lung function and the quality of life, yet robust evidence remains limited. Regulatory guidelines vary, emphasizing the cautious application of ULABAs in children, particularly under 12 years, due to concerns about adverse effects and optimal dosing. Future research should address these gaps, focusing on long-term safety, efficacy, and the role of personalized approaches to optimize asthma outcomes in this vulnerable population.